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THE WOMEN’S HEALTH INITIA-tive (WHI) trial of estrogen plusprogestin was a randomized,controlled,double-blind trialde-
signed to determine the effects of estro-
gen plus progestin compared with pla-
cebo on a number of important chronic
diseases of older women.1 After an av-
erage follow-up of 5.2 years, the trial was
stopped early because of safety con-
cerns. Hip and clinical vertebral frac-
tures were significantly reduced by 34%
and total osteoporotic fractures by 24%.
However, the overall risk-benefit pro-
file of estrogen plus progestin, summa-
rized in a global index, was not consis-
tent with a viable intervention for
primary prevention of chronic diseases
in postmenopausal women.
This article provides an updated fi-
nal analysis of fracture end points
Author Affiliations, Financial Disclosures, andWom-
en’s Health Initiative investigators are listed at the
end of this article.
Corresponding Author and Reprints: Jane A. Cau-
ley, DrPH,University of Pittsburgh, CrabtreeHall A524,
130 DeSoto St, Pittsburgh, PA 15261 (e-mail: jcauley
@pitt.edu).
Context In the Women’s Health Initiative trial of estrogen-plus-progestin therapy,
women assigned to active treatment had fewer fractures.
Objective To test the hypothesis that the relative risk reduction of estrogen plus pro-
gestin on fractures differs according to risk factors for fractures.
Design, Setting, and Participants Randomized controlled trial (September 1993-
July 2002) in which 16608 postmenopausal women aged 50 to 79 years with an in-
tact uterus at baseline were recruited at 40 US clinical centers and followed up for an
average of 5.6 years.
Intervention Women were randomly assigned to receive conjugated equine estro-
gen, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n=8506)
or placebo (n=8102).
Main Outcome Measures All confirmed osteoporotic fracture events that oc-
curred from enrollment to discontinuation of the trial ( July 7, 2002); bonemineral den-
sity (BMD), measured in a subset of women (n=1024) at baseline and years 1 and 3;
and a global index, developed to summarize the balance of risks and benefits to test
whether the risk-benefit profile differed across tertiles of fracture risk.
Results Seven hundred thirty-three women (8.6%) in the estrogen-plus-progestin
group and 896 women (11.1%) in the placebo group experienced a fracture (hazard
ratio [HR], 0.76; 95% confidence interval [CI], 0.69-0.83). The effect did not differ in
women stratified by age, body mass index, smoking status, history of falls, personal
and family history of fracture, total calcium intake, past use of hormone therapy, BMD,
or summary fracture risk score. Total hip BMD increased 3.7% after 3 years of treat-
mentwith estrogen plus progestin comparedwith 0.14% in the placebo group (P.001).
The HR for the global index was similar across tertiles of the fracture risk scale (lowest
fracture risk tertile, HR, 1.20; 95% CI, 0.93-1.58; middle tertile, HR, 1.23; 95% CI,
1.04-1.46; highest tertile, HR, 1.03; 95% CI, 0.88-1.24) (P for interaction=.54).
Conclusions This study demonstrates that estrogen plus progestin increases BMD
and reduces the risk of fracture in healthy postmenopausal women. The decreased
risk of fracture attributed to estrogen plus progestin appeared to be present in all sub-
groups of women examined. When considering the effects of hormone therapy on
other important disease outcomes in a global model, there was no net benefit, even in
women considered to be at high risk of fracture.
JAMA. 2003;290:1729-1738 www.jama.com
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through the termination of the trial on
July 7, 2002. We also tested the hy-
pothesis that the relative risk reduc-
tion of estrogen plus progestin on frac-
ture differed by risk factors for fracture.
We report the lumbar spine and total
hip bone mineral density (BMD) out-
comes for the subset of study partici-
pants undergoing this assessment. Fi-
nally, we tested the hypothesis that the
risk-benefit profile of treatment with es-
trogen plus progestin differed across ter-
tiles of fracture risk.
METHODS
Overview
Details of the WHI design are reported
elsewhere.1,2 In brief, 16608 postmeno-
pausal women with an intact uterus who
were aged 50 to 79 years at baseline were
randomized to either conjugated equine
estrogen, 0.625 mg/d, and medroxypro-
gesterone acetate, 2.5 mg/d, in a single
tablet (n=8506) or placebo (n=8102)
and followed up for an average of 5.6
years (FIGURE 1). Trial recruitment be-
gan in September 1993 with the first ran-
domization in December 1993. Fol-
low-up is ongoing, but the intervention
was terminated approximately 3 years
earlier than planned because of an ad-
verse effect on breast cancer and an ex-
cess risk of events as determined by the
global indexassessment summarizing the
balance of risks and benefits.1 The pro-
tocol and consent forms were approved
by the institutional review boards of all
participating institutions and all women
provided written informed consent.
Risk Factors for Osteoporosis
Information on baseline risk factors for
fractures was assessed in a standardized
manner by questionnaire, interview, and
clinical examination. Weight was mea-
sured on a balance beam scale while
wearing indoor clothing. Height was
measured with a fixed stadiometer.
Weight and height were used to calcu-
late body mass index (BMI; weight in ki-
lograms divided by the square of height
in meters). Race/ethnicity categoriza-
tion was based on self-declaration. In-
formation on falls, fracture history, fam-
ily history of fracture, smoking, alcohol
consumption, and general health status
was obtained by questionnaire. Dietary
calcium intake was assessed using a
modification of the Block food fre-
quency questionnaire and expressed in
milligrams per day.3 Information on use
of calcium supplements in the previous
2 weeks was obtained by an interviewer-
administeredmedication inventory.Total
calcium intake was derived from the sum
of dietary and supplemental sources.
Information on medication use at
baseline included use of estrogen, pro-
gestin, thiazide diuretics, and thyroid
medications. Participants were asked to
bring all medications, vitamins, and
supplements to the clinic for verifica-
tion of current use. Information on past
use of hormone therapy was collected
by questionnaire. Women were ex-
cluded if they reported use of tamoxi-
fen. Women using postmenopausal
hormones at the initial screening could
be enrolled after a 3-month washout pe-
riod. Information was collected on use
of other antiresorptive agents at base-
line and follow-up years 1, 3, and 6. If
a woman initiated open-label use of hor-
mone therapy or any selective estro-
gen receptor modulator after random-
ization, she was required to discontinue
study medications.
Outcomes
Reports of hip, vertebral, and other os-
teoporotic fractures except those of the
ribs, chest/sternum, skull/face, fingers,
toes, and cervical vertebrae were ascer-
tained by a semiannual questionnaire. If
a fracturewasreported,radiologyreports
were obtained. The initial report of the
WHI estrogen-plus-progestin trial was
based on local adjudication.1 In this re-
port, hip fractures were centrally adju-
dicated.Theagreementbetweenlocaland
central adjudication for hip fracture was
94%. All other fractures at clinical cen-
ters where BMD was not measured were
locallyadjudicated.Alladjudicatorswere
blinded to treatment assignment. Frac-
tureoutcomes includedhip,wrist/lower
arm,clinicalvertebral,andtotal fractures.
In an attempt to summarize impor-
tant aspects of health benefits vs risk, a
global index was created that included
the earliest occurrence of coronary heart
disease, invasive breast cancer, stroke,
pulmonary embolus, endometrial can-
cer, colorectal cancer, hip fracture, or
death due to other causes.1 Compared
with total mortality, which may be rela-
tively insensitive, this index summa-
rizes differences in the incidence of the
7 listed diseases as well as other causes
of mortality. The global index of these
outcomesplayedasupportiverole in trial
monitoring as the summary measure of
the overall balance of risks and benefits.
Bone Mineral Density
Bonemineraldensityof the lumbarspine
(L2-L4), and total hip was measured by
dual x-ray absorptiometry (QDR 2000,
2000+, or 4500W, Hologic Inc, Bed-
Figure 1. Flow of Study Participants
373 092 Women Initiated Screening
8506 Included in Analysis 8102 Included in Analysis
8506 Assigned to Receive Estrogen + Progestin 8102 Assigned to Receive Placebo
18 845 Provided Consent and Reported No Hysterectomy
16 608 Women Randomized
Status on July 7, 2002
7962 Alive and Outcomes Data Submitted in
Last 18 mo
296 Unknown Vital Status
248 Deceased
Status on July 7, 2002
7620 Alive and Outcomes Data Submitted in
Last 18 mo
245 Unknown Vital Status
237 Deceased
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ford, Mass) in 3 of the 40 US clinical cen-
ters (Pittsburgh, Pa, Birmingham, Ala,
and Tucson/Phoenix, Ariz). At these 3
BMD centers, women were excluded if
their femoral neck BMD was more than
3 SDs below the corresponding age-
specificmean(Zscore−3.0).Bonemin-
eraldensitywasmeasuredatbaselineand
years1,3,and6.Because fewwomenhad
yet had BMD measured at year 6, our
analyses are confined to measurements
at baseline plus years 1 and 3. The BMD
clinical centers were chosen to provide
maximum racial diversity.
Standard protocols for positioning and
analysis were used by technologists who
were trained and certified by the Uni-
versity of California, San Francisco bone
densitometry reading center. The on-
going quality assurance program was
similar to that used in other studies.4
Statistical Analysis
All primary analyses used time-to-event
methods and are based on the intention-
to-treat principle. Outcome compari-
sonsarepresentedashazardratios (HRs)
and nominal 95% confidence intervals
(nCIs) from Cox proportional hazards
analyses stratified by age, prior fracture
history, and randomization status in the
low-fat diet and calcium/vitamin D trials
of the WHI. The calcium/vitamin D trial
is a randomized clinical trial testing
whether calcium and vitamin D supple-
ments decrease the risk of hip fracture.
Equalproportionsofwomenintheestro-
gen-plus-progestin and placebo groups
participated in the calcium/vitamin D
trial. Nominal 95% CIs are presented
throughout except for the hip fracture
outcome, which was 1 of 7 outcomes
monitored by the data and safety moni-
toring board. To account for the mul-
tiple outcomes, we also present adjusted
95% CIs (aCIs) for hip fracture, as was
specified in the trial monitoring plan.
Because a substantial number of
women (42% taking estrogen plus pro-
gestin and 36% taking placebo) stopped
taking their study medications at some
point during the follow-up period,1 we
examined the sensitivity of the HR esti-
mates and BMD changes to actual use of
study medications. In these analyses, par-
Table 1. Baseline Characteristics by Randomization Assignment*
Characteristics
Estrogen + Progestin
(n = 8506)
Placebo
(n = 8102)
P
Value
Age at screening, y
50-59 2839 (33.4) 2683 (33.1)
60-69 3853 (45.3) 3657 (45.1) .80
70-79 1814 (21.3) 1762 (21.8)
Mean (SD) 63.2 (7.10) 63.3 (7.10) .39
Years since menopause
10 2782 (36.23) 2712 (36.12)
10-19 3047 (39.68) 2994 (39.87) .97
20 1850 (24.09) 1803 (24.01)
Race/ethnicity
White 7140 (83.9) 6805 (84.0)
Black 549 (6.5) 575 (7.1)
Hispanic 472 (5.6) 416 (5.1)
.33
American Indian 26 (0.3) 30 (0.4)
Asian/Pacific Islander 194 (2.3) 169 (2.1)
Unknown 125 (1.5) 107 (1.3)
Height, mean (SD), cm 161.5 (6.60) 161.7 (6.50) .19
Weight, mean (SD), kg 74.5 (16.40) 74.8 (16.80) .19
Weight57 kg (127 lb) 1078 (12.7) 993 (12.3) .42
Body mass index†
25 2579 (30.5) 2479 (30.8)
25 to30 2992 (35.3) 2834 (35.2) .89
30 2899 (34.2) 2737 (34.0)
Mean (SD) 28.5 (5.80) 28.5 (5.90) .66
Total calcium intake, mg/d
600 2002 (24.4) 1894 (24.2)
600-1200 3329 (40.5) 3159 (40.3) .85
1200 2882 (35.1) 2783 (35.5)
Baseline thiazide diuretic use 414 (4.9) 395 (4.9) .98
Baseline thyroid medication use 875 (10.3) 876 (10.8) .27
General health
Fair/poor 530 (6.3) 556 (6.9)
.10
Good/very good/excellent 7927 (93.9) 7493 (93.1)
Hormone therapy use
Never 6277 (73.8) 6020 (74.3)
Past 1671 (19.7) 1588 (19.6) .47
Current use at baseline 554 (6.5) 491 (6.1)
Hormone therapy duration of use, y
5 1539 (69.0) 1470 (70.6)
5 to10 427 (19.2) 356 (17.1) .22
10 263 (11.8) 255 (12.3)
Smoking
Never 4178 (49.6) 3999 (50.0)
Past 3362 (39.9) 3157 (39.5) .85
Current 880 (10.5) 838 (10.5)
No. of falls in past 12 mo
0 5168 (66.2) 5172 (67.5)
1 1643 (21.0) 1545 (20.2) .22
2 1000 (12.8) 948 (12.4)
History of fracture 2950 (38.8) 2947 (39.1) .72
Maternal history of hip fracture after age 40 y 887 (12.4) 873 (12.5) .84
Parental history of fracture after age 40 y 3182 (40.5) 3012 (40.3) .80
Total hip BMD, mean (SD), g/cm2‡ 0.83 (0.13) 0.84 (0.14) .77
Total hip BMD T score, mean (SD)‡ −0.94 (0.98) −0.91 (1.04) .79
(continued)
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ticipants’ outcome data were censored 6
months after they became nonadherent
(taking80% of or stopping study drug
or initiatingnonstudyhormone therapy).
The mean follow-up time in the sensi-
tivity analysis was 3.7 years.
The effect modification of fracture risk
with estrogen plus progestin by poten-
tial risk factors was assessed by Cox pro-
portional hazards analyses with tests of
interaction between the risk factor and
treatment assignment. Women were di-
vided into groups based on age, race/
ethnicity, BMI,5 history of fracture, past
use of hormone therapy, falls in the pre-
vious 12 months, parental history of frac-
ture, and total calcium intake. In a
subgroup of women with BMD measure-
ments (n=1024), we also examined
strata defined by a T score of less than
−2.5 at the lumbar spine, total hip, or
femoral neck using the National Health
and Nutrition Examination Survey ref-
erence database for the hip and the
manufacturer’s database for the spine.
The race/ethnicity and BMD stratifica-
tions were limited to total fractures. We
report nominal P values throughout. In
this risk factor analysis, we explored
more than 100 subgroups and, by chance
alone, at least 5 would be expected to be
statistically significant at theP=.05 level.
We developed a summary fracture risk
score in the placebo group using meth-
ods developed by Black et al.6 Their in-
dex identified 20 fracture risk factors. We
did not have hip BMD measurements for
all women, nor did we have informa-
tion on use of arms to stand from a chair,
“4 or fewer hours on feet per day,” or
height at age25years.Our summary frac-
ture risk score used current height and
included race/ethnicity. Variables that
were significant (P.10) in the indi-
vidual age-adjusted logistic regressionhip
fracture models were entered into a mul-
tivariable model and included age, non-
black race/ethnicity, prior fracture after
age 55 years, fall in past 12 months, cur-
rent smoking, BMI of 22.4 or less, and
no walking for exercise. Age, prior frac-
ture, current smoking, and BMI were all
significant (P.05) and were included
in the final risk factor set. The sum-
mary fracture risk score was computed
as described by Black et al.6 Briefly, us-
ing the additive properties of the logis-
tic function, the coefficients from the fi-
nal model were multiplied by a constant,
rounded to the nearest integer, multi-
plied by each individual’s risk factor val-
ues, and then summed. The area under
the receiveroperatingcharacteristic curve
for the final model was 0.785 (95% CI,
0.73-0.84) for hip fracture, indicating
moderate predictive strength.
Absolute differences and percentage
changes in BMD of the lumbar spine and
total hip from baseline to year 1 and to
year 3 were calculated. We used linear
regression to compare the rates of change
in BMD in women randomized to es-
trogen plus progestin vs placebo in the
entire population with BMD and in
medication-adherent women. We ad-
justed for clinic site and race/ethnicity.
To test whether the risk-benefit pro-
file of estrogen plus progestin differed
in women according to their risk of hip
fracture, we examined the HR (95% CI)
of the global index across tertiles of the
summary fracture risk score. All analy-
ses were performed using SAS statisti-
cal software, version 8.02 (SAS Insti-
tute Inc, Cary, NC).
RESULTS
Baseline characteristics including risk
factors for fracture were similar in the
8506 women randomized to estrogen
plus progestin and the 8102 women in
the placebo group (TABLE 1). The mean
age of the women was 63 years; 44%
were older than 65 years. Examination
of risk factors for fractures revealed that
74% had no prior history of hormone
use; 10% were current smokers; 39% had
a personal history of fracture; 12% re-
ported a maternal history of hip frac-
ture; 33% reported at least 1 fall in the
previous 12 months; 14% had experi-
enced at least 1 fracture after age 55
years; and 23% were considered to be
at higher risk of fracture based on our
summary fracture risk score. Use of a bi-
sphosphonate at baseline was low (ap-
proximately 1%) but increased to about
6% among women in the estrogen-plus-
progestin group and to 10% among
women in the placebo group by year 6.
Use of raloxifene and calcitonin was low
in each group (2%) by year 6.
In the subgroup of 1024 women with
BMD measurements, there was no dif-
ference in baseline BMD by treatment
randomization (Table 1). Only 4% of
women in the estrogen-plus-proges-
tin group and 6% of women in the pla-
cebo group were considered to have os-
teoporosis at the total hip using World
Health Organization criteria.7
We compared the characteristics of
women in the BMD subsample with the
remaining women. As expected, there
were larger proportions of nonwhite
women and women reporting never us-
ing hormones in the BMD subsample.
This may have reflected the lower
prevalence of hormone use among mi-
nority women.8 Other risk factors for
fracture, such as age and body weight,
did not differ.
Fractures
A total of 733 women (8.6%) in the es-
trogen-plus-progestin group and 896
(11.1%) in the placebo group experi-
Table 1. Baseline Characteristics by Randomization Assignment* (cont)
Characteristics
Estrogen + Progestin
(n = 8506)
Placebo
(n = 8102)
P
Value
Spine BMD, mean (SD), g/cm2‡ 0.94 (0.16) 0.95 (0.16) .87
Spine BMD T score, mean (SD)‡ −1.30 (1.39) −1.26 (1.42) .87
Summary fracture risk score
0-2 (Low) 2393 (34.5) 2350 (34.4)
3-5 (Moderate) 2691 (42.7) 2910 (42.6) .93
5 (High) 1575 (22.7) 1571 (23.0)
Abbreviation: BMD, bone mineral density.
*Data are expressed as No. (%) unless otherwise specified. Denominators for percentages differ because of missing
data.
†Body mass index was calculated as weight in kilograms divided by the square of height in meters.
‡Analyzed in a subset of participants in the estrogen-plus-progestin (n = 546) and placebo (n = 478) groups.
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enced a fracture during the follow-up
period of 5.6 years. There were 52 hip
fractures in the treatment group and 73
in the placebo group. There were 189
lower arm/wrist fractures in the treat-
ment group and 245 in the placebo
group; there were 41 clinical vertebral
fractures in the treatment group and 60
in the placebo group. Overall fracture
rates per 10000 person-years in the es-
trogen-plus-progestin and placebo
groups, respectively, were: hip frac-
ture, 11 and 16; wrist/lower arm, 44 and
62; clinical vertebral, 11 and 17; and
total fractures, 152 and 199.
Estrogen plus progestin reduced the
risk of hip fracture by 33% (HR, 0.67;
95% nCI, 0.47-0.96; 95% aCI, 0.41-
1.10) (TABLE 2). In subgroup analyses,
estrogenplusprogestindecreased the risk
of hip fracture by 60% among women
who reported a baseline calcium intake
of more than 1200 mg/d but not among
women with lower calcium intake (P for
interaction=.02). Estrogen plus proges-
tin reduced the risk of hip fracture in
women with a BMI of less than 25 (HR,
0.50; 95% nCI, 0.28-0.90) and with a
BMI of 25 to less than 30 (HR, 0.67; 95%
nCI, 0.37-1.20) but not in women with
a BMI of 30 or more; however, the in-
teraction of hormone therapy with BMI
was not statistically significant (P=.41).
The risk of hip fracture was reduced by
estrogen plus progestin to a similar de-
gree in women stratified by age, smok-
ing, fall and fracture history, past use of
hormone therapy, parental fracture his-
tory, years since menopause, and sum-
mary fracture risk score.
Hazard ratios for total fractures were
also lower for women randomized to
estrogen plus progestin in virtually all
subgroups examined and did not differ
fromtheoverallHR(TABLE3).Therewas
no significant interaction between treat-
ment assignment and race/ethnicity for
total fractures. When participants were
stratifiedbysummary fracture riskscore,
the annualized incidence of total frac-
tures in the placebo group was 1.3%,
2.0%,and2.7%inthe lowest,middle,and
highest risk groups, respectively, with
similar HRs for total fractures (HR, 0.82;
95% nCI, 0.66-1.02 for the lowest risk
group; HR, 0.68; 95% nCI, 0.58-0.81 for
themiddleriskgroup;andHR,0.85;95%
nCI,0.70-1.03 for thehighest riskgroup)
(Table 3). The HR for all nonspine frac-
tures was 0.75 (95% nCI, 0.68-0.83).
Time Trends
The Kaplan-Meier estimates of cumula-
tive hazards for each type of fracture in-
dicated that thedifferencesbetween treat-
ment groups began to develop soon after
randomization and implementation of
the study medication (FIGURE 2). The
difference in the cumulative incidence of
fractures between women assigned to es-
trogen plus progestin and those as-
signed to placebo increased over time.
The Kaplan-Meier curves suggest con-
Table 2. Hazard Ratio of Hip Fracture by Randomization Assignment and Stratification*
Outcomes
Estrogen + Progestin,
No. (%)
(N = 8506)†
Placebo,
No. (%)
(N = 8102)†
Hazard Ratio
(95% Nominal
Confidence
Interval)
P Value for
Interaction
Total population 52 (0.11) 73 (0.16) 0.67 (0.47-0.96)
Age at screening, y
50-59 1 (0.01) 5 (0.03) 0.17 (0.02-1.43)
60-69 19 (0.09) 23 (0.11) 0.76 (0.41-1.39) .72
70-79 32 (0.33) 45 (0.48) 0.69 (0.44-1.08)
Years since menopause
10 2 (0.01) 2 (0.01) 0.95 (0.13-6.75)
10-19 17 (0.10) 21 (0.13) 0.80 (0.42-1.53) .54
20 27 (0.27) 44 (0.46) 0.58 (0.36-0.94)
Body mass index‡
25 18 (0.12) 34 (0.24) 0.50 (0.28-0.90)
25 to 30 19 (0.11) 27 (0.17) 0.67 (0.37-1.20) .41
30 15 (0.09) 12 (0.08) 1.11 (0.52-2.39)
Smoking
Current 7 (0.14) 10 (0.21) 0.65 (0.24-1.71)
.76
Never/past 45 (0.11) 59 (0.15) 0.73 (0.49-1.07)
No. of falls in past 12 mo
0 30 (0.11) 41 (0.15) 0.73 (0.45-1.16)
1 11 (0.12) 15 (0.18) 0.73 (0.33-1.60) .17
2 7 (0.12) 16 (0.30) 0.39 (0.16-0.96)
Total calcium intake
at baseline, mg/d
600 15 (0.13) 14 (0.13) 0.94 (0.45-1.96)
600-1200 24 (0.13) 25 (0.14) 0.91 (0.52-1.59) .02
1200 13 (0.08) 31 (0.20) 0.40 (0.21-0.76)
Parental history of fracture
No 26 (0.10) 40 (0.16) 0.63 (0.38-1.04)
.54
Yes 22 (0.12) 26 (0.15) 0.77 (0.44-1.36)
History of hormone therapy, y
Never 45 (0.13) 54 (0.16) 0.79 (0.53-1.18)
5 2 (0.02) 15 (0.18) 0.13 (0.03-0.56)
.57
5 to 10 3 (0.12) 3 (0.15) 0.57 (0.11-2.92)
10 2 (0.14) 1 (0.07) 0.13 (0.03-0.56)
History of fracture
No 15 (0.06) 28 (0.11) 0.52 (0.28-0.98)
.34
Yes 31 (0.19) 41 (0.26) 0.77 (0.48-1.22)
Summary fracture risk score
0-2 (Low) 0 3 (0.02) Not applicable
3-5 (Moderate) 15 (0.09) 18 (0.12) 0.81 (0.41-1.61) .35
5 (High) 28 (0.34) 40 (0.49) 0.70 (0.43-1.13)
*All proportional hazards models were stratified by age (50-54, 55-59, 60-69, or 70-79 years), prior hip fracture, diet
modification randomization group, and calcium/vitamin D randomization group, except for models by age (not strati-
fied by age) and models by prior fracture (not stratified by prior fracture).
†Data are expressed as number of women with fractures (annualized percentage).
‡Body mass index was calculated as weight in kilograms divided by the square of height in meters.
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tinuing beneficial effects of estrogen plus
progestin on fracture reduction through-
out the observation period.
Sensitivity Analysis
Exclusion of follow-up time for non-
adherence had little effect on the HRs
(hip fracture, HR, 0.63; 95% nCI, 0.38-
1.06; wrist/lower arm, HR, 0.67; 95%
nCI, 0.54-0.84; vertebral fracture, HR,
0.60; 95% nCI, 0.38-0.95; total frac-
tures, HR, 0.72; 95% nCI, 0.64-0.81).
Bone Mineral Density
Estrogen plus progestin showed con-
sistent positive effects on BMD. Total
hip BMD increased a mean of 1.7% dur-
ing the first year of estrogen-plus-
progestin treatment and improved by
3.7% by year 3 compared with a loss of
0.44% at year 1 and a 0.14% improve-
ment at year 3 in the placebo group
(P.001) (FIGURE 3A). Similar find-
ings were observed at the lumbar spine
(Figure 3B). After 1 year of hormone
therapy, the mean percentage change
in BMD was 3.3% higher at the lum-
bar spine and 2.1% higher at the total
hip. After 3 years of treatment, the per-
centage difference in favor of hor-
mone therapy was greater, with mean
differences of 4.5% and 3.6% at the lum-
bar spine and total hip, respectively. A
total of 194 (36%) women in the es-
trogen-plus-progestin group and 249
(32%) in the placebo group had a year
6 BMD measurement. By year 6, the per-
centage increase in lumbar spine BMD
was 7.5% in women in the estrogen-
plus-progestin group compared with
2.6% in the placebo group. Sensitivity
analyses limited to adherent women re-
vealed larger increases in BMD; the av-
erage percentage increase in BMD from
baseline to year 3 was 7.6% in the lum-
bar spine and 4.5% in the total hip
among women randomized to estro-
gen plus progestin compared with 1.5%
and −0.3%, respectively, among women
randomized to placebo.
Global Index
Among women in the lowest tertile of
fracture risk based on our summary
fracture risk score, the global index HR
Table 3. Hazard Ratio of Total Fractures by Randomization Assignment and Stratification*
Outcomes
Estrogen + Progestin,
No. (%)
(N = 8506)†
Placebo,
No. (%)
(N = 8102)†
Hazard Ratio
(95% Nominal
Confidence Interval)
P Value for
Interaction
Total population 733 (1.52) 896 (1.99) 0.76 (0.69-0.83)
Age at screening, y
50-54 67 (1.05) 90 (1.53) 0.68 (0.49-0.93)
55-59 124 (1.18) 126 (1.29) 0.91 (0.71-1.16)
60-64 168 (1.53) 184 (1.85) 0.80 (0.65-0.98)
.47
65-69 161 (1.53) 238 (2.35) 0.68 (0.49-0.93)
70-74 142 (2.11) 174 (2.61) 0.81 (0.65-1.01)
75-79 71 (2.38) 84 (3.09) 0.73 (0.53-1.00)
Years since menopause
10 187 (1.17) 221 (1.44) 0.80 (0.66-0.98)
10-19 255 (1.55) 327 (2.03) 0.75 (0.64-0.89) .95
20 200 (2.03) 257 (2.69) 0.74 (0.61-0.89)
Body mass index‡
25 237 (1.62) 312 (2.25) 0.71 (0.60-0.84)
25 to 30 245 (1.44) 308 (1.94) 0.75 (0.63-0.89) .18
30 246 (1.51) 270 (1.79) 0.82 (0.69-0.97)
Smoking
Current 71 (1.45) 84 (1.80) 0.79 (0.57-1.08)
.77
Never/past 656 (1.54) 795 (2.00) 0.76 (0.69-0.84)
Falls in past 12 mo
0 392 (1.40) 519 (1.85) 0.74 (0.65-0.85)
1 145 (1.59) 169 (1.99) 0.82 (0.65-1.02) .84
2 115 (2.05) 139 (2.65) 0.76 (0.59-0.97)
Total calcium intake
at baseline, mg/d
600 171 (1.50) 204 (1.93) 0.78 (0.64-0.96)
600-1200 293 (1.56) 359 (2.02) 0.76 (0.65-0.89) .81
1200 249 (1.53) 304 (1.98) 0.76 (0.64-0.89)
Parental history of fracture
No 356 (1.35) 465 (1.87) 0.71 (0.62-0.82)
.28
Yes 320 (1.77) 368 (2.19) 0.80 (0.69-0.93)
History of hormone therapy, y
Never 555 (1.57) 678 (2.03) 0.76 (0.68-0.85)
5 109 (1.23) 149 (1.79) 0.70 (0.55-0.90) .39
5 to 10 42 (1.72) 37 (1.88) 0.80 (0.51-1.26)
10 27 (1.89) 32 (2.30) 0.70 (0.55-0.90)
Race/ethnicity
White 673 (1.66) 823 (2.16) 0.76 (0.69-0.84)
Black 21 (0.68) 36 (1.15) 0.58 (0.34-1.00)
Hispanic 18 (0.71) 17 (0.76) 0.79 (0.40-1.56)
.77
American Indian 1 (0.69) 2 (1.28) Not applicable
Asian/Pacific Islander 10 (0.97) 10 (1.12) 0.71 (0.28-1.79)
Unknown 10 (1.50) 8 (1.43) 1.25 (0.47-3.35)
History of fracture
No 298 (1.18) 391 (1.57) 0.74 (0.63-0.86)
.59
Yes 330 (2.07) 417 (2.62) 0.78 (0.68-0.91)
Baseline BMD T score 2.5 SD
below young normal§
No 44 (1.69) 43 (1.90) 0.87 (0.57-1.34)
.15
Yes 11 (1.44) 22 (3.16) 0.53 (0.25-1.10)
Summary fracture risk score
0-2 (Low) 149 (1.10) 175 (1.33) 0.82 (0.66-1.02)
3-5 (Moderate) 224 (1.41) 312 (1.99) 0.68 (0.58-0.81) .65
5 (High) 191 (2.33) 223 (2.71) 0.85 (0.70-1.03)
*All proportional hazards models were stratified by age (50-54, 55-59, 60-69, or 70-79 years), any prior fracture, diet
modification trial randomization group, and calcium/vitamin D trial randomization group except models by age (not
stratified by age) and models by prior fracture (not stratified by prior fracture).
†Data are expressed as number of women with fractures (annualized percentage).
‡Body mass index was calculated as weight in kilograms divided by the square of height in meters.
§Bone mineral density (BMD) from total hip, femoral neck, or spine (L2-L4); n = 1024.
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was 1.20 (95% nCI, 0.93-1.58); in the
middle tertile of risk, the HR was 1.23
(95% nCI, 1.04-1.46); and in the high-
est tertile of risk, the HR was 1.03 (95%
nCI, 0.88-1.24). The interaction be-
tween treatment effect and summary
fracture risk on the global index was not
significant (P=.54). Thus, there was no
evidence of a net benefit, even in
women at high risk of fracture.
COMMENT
The WHI estrogen-plus-progestin trial
is the first randomized clinical trial
demonstrating that combination post-
menopausal hormone therapy re-
duces the risk of fractures at the hip,
vertebrae, and wrist. These findings are
consistent with observational data9,10
and several recent meta-analyses of the
efficacy of hormone therapy in reduc-
tion of fractures in postmenopausal
women.11-13 Torgersen and Bell-Syer12
reported a greater effect among women
younger than 60 years with little or no
benefit observed among older women.
However, this conclusion was primar-
ily based on one study in each age
group.14 In the WHI, we found no evi-
dence that the effect differed by age or
time since menopause.
Figure 2. Kaplan-Meier Estimates of Cumulative Hazards for Fracture
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The overall benefit vs risk of estrogen-
plus-progestin therapy is a central fo-
cus of the WHI. Overall, the global in-
dex showed a nominally significant 15%
increase in the estrogen-plus-progestin
group, indicating more harm than ben-
efit in women randomized to hormone
therapy.1 Since estrogen plus progestin
has shown a beneficial effect on frac-
ture incidence, there is interest in de-
termining whether there might be a sub-
group of women at high risk of fracture
for whom the benefits from estrogen plus
progestin would outweigh the risks. In
the analyses described here, we found
no evidence that the efficacy of estro-
gen plus progestin differed according to
any risk factors for fractures, including
age, BMI, smoking, history of falls, cal-
cium intake, personal and family his-
tory of fracture, and past use of hor-
mones. Risk factors for fracture were
combined in a summary fracture risk
score, and we found that estrogen plus
progestin reduced fractures to a similar
degree in women who were considered
at low, medium, and high risk of frac-
ture. Even among women who were
considered at high risk of fracture, the
HR for the global index did not indi-
cate net benefit. These results imply that
the benefit of fracture reduction does not
outweigh the risks of cardiovascular dis-
ease and breast cancer, even in women
at higher risk of fracture. In addition, the
fracture risk score gives substantial
weight to increasing age, and another
analysis of WHI data found a 2-fold in-
crease in dementia among women aged
65 years or older who were random-
ized to estrogen plus progestin vs those
randomized to placebo.15
The WHI is the first randomized con-
trolled trial to include a large group of
nonwhite women. Among black
women, estrogen plus progestin re-
duced the risk of total fractures by 42%;
however, this outcome did not achieve
statistical significance because of the
small number of fractures in this sub-
group of women. Nevertheless, there
was no evidence of an interaction be-
tween treatment and race/ethnicity.
Treatment with estrogen plus proges-
tin resulted in consistent positive ef-
fects on BMD in the lumbar spine and
total hip. Similar to other antiresorp-
tive therapies, the increase in BMD was
greatest in the lumbar spine, a site that
contains a large proportion of trabecu-
lar bone. The differences in BMD that
we observed between the estrogen-plus-
progestin group and the placebo group
were consistent with results from a re-
cent meta-analysis of hormone therapy
for prevention and treatment of osteo-
porosis in postmenopausal women.11
Unlike in other randomized trials of
osteoporosis treatments, women en-
rolled in the WHI were, for the most
part, healthy. Hip fracture rates were
about 50% lower than expected for a
similar age-matched cohort.16 Al-
though BMD measurements were con-
fined to a small sample of the enrollees,
a relatively small proportion of women
in the WHI had osteoporosis at the base-
line assessment. Hence, the study re-
sults are likely to be applicable to healthy
postmenopausal women. The bisphos-
phonate trials showed a reduction in risk
of hip and nonspine fractures in women
with osteoporosis but not in women
without osteoporosis.17-20 It may be that
treatment with estrogen plus progestin
reduces fractures in women without os-
teoporosis through a reduction in falls
and improvement in muscle strength, al-
though the evidence for this is sparse and
conflicting.21-23 Other trials that have ex-
amined fracture reduction in partici-
pants without osteoporosis are limited
by the small number of participants, and
the failure to observe a treatment effect
may be a consequence of inadequate sta-
tistical power to detect an effect.
In the Heart and Estrogen/Progestin
ReplacementStudy(HERS), therewasno
effect of estrogen-progestin therapy on
clinical fractures.24,25 Indeed, contin-
ued open-label follow-up of the women
in HERS reported ahigher rate of hip frac-
ture among women originally random-
ized toestrogenplusprogestin.26 The lack
of observed benefit on fractures in HERS
was interpreted as being consistent with
the lack of benefit observed with other
agents in women without osteoporo-
sis.19,20 It is not apparent why the WHI
and HERS findings differ because both
trials enrolled women without osteopo-
rosis. The women in HERS were, on av-
erage, slightly older and all had coro-
nary heart disease and reported a higher
prevalence of medications such as ni-
trates27 and statins28 that may influence
bone.Finally, the sample sizeofWHIwas
much larger than that of HERS, which
may have provided the necessary power
to detect a treatment effect.
Strengths of the WHI include its ran-
domized design, large sample size of eth-
nically diverse postmenopausal women
across a wide age range, complete fol-
low-up for outcomes on 93% of the
women randomized, and confirmation
of all fractures by medical record. There
Figure 3. Mean Percentage Change in Total Hip and Spine BMD During 3 Years of
Follow-up
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are, however, a number of limitations.
Only one estrogen-progestin formula-
tion was tested, although it was the most
commonly prescribed postmenopausal
hormone therapy regimen in the United
States at the time the study was de-
signed. Furthermore, no prior trials have
demonstrated differential effects by type
of estrogen or for unopposed or combi-
nation therapy on BMD.11 The WHI es-
trogen-only trial is ongoing, with
completion anticipated in 2005. Frac-
tures are also secondary end points of
that randomized trial.
A number of screening tools have been
developed to identify women with os-
teoporosis. For the most part, these tools
have only poor to moderate specificity
and have not been validated in popula-
tions other than the ones for which they
were created.29 We developed a sum-
mary fracture risk score using risk fac-
tors for hip fracture similar to the method
developed by Black et al.6 While this
score correlated with the risk of frac-
ture, the ratio of highest to lowest risk
was modest (2.0). Bone mineral density
and prevalent vertebral fractures are
stronger predictors of future frac-
ture,29,30 but we did not collect these data
for all women in the trial; hence, we were
unable to identify a group of women with
severe osteoporosis in whom the ben-
efits of estrogen plus progestin might ex-
ceed the risks.
We tested for interactions of estro-
gen plus progestin with a number of risk
factors for fracture; none were signifi-
cant. However, differential benefit could
occur in the absence of significant in-
teractions if the baseline risk of frac-
ture is different in the various sub-
groups. For example, the absolute risk
of fracture was 2-fold higher in the high-
risk fracture group compared with the
low-risk group. Hence, even if the HRs
did not differ in the 2 groups, the ab-
solute number of fractures prevented
would be greater in the high-risk group.
The WHI enrolled a large group of eth-
nically diverse women, but we had lim-
ited power to test for an interaction be-
tween treatment and race/ethnicity. We
had a relatively high rate of discontinu-
ation of study drug in the active treat-
ment group, but sensitivity analyses lim-
ited to adherent women yielded similar
results. Assessment of vertebral frac-
tures was limited to clinically symptom-
atic fractures, which represent only about
one third of all vertebral fractures.31 Fi-
nally, the global index was designed to
focus on potentially life-threatening
events and therefore included hip frac-
tures, which have been shown to have
significant morbidity32 and mortality,33
but not other fractures, such as verte-
bral fractures. Vertebral fractures have
also been associated with an increased
risk of mortality34 and disability.35 In a
separate analysis, the overall balance of
risks and benefits of hormone therapy on
quality of life did not show a clinically
significant benefit.36
In conclusion, estrogen plus proges-
tin increases BMD and reduces the risk
of fracture in healthy postmenopausal
women and appears to do so regardless
of presence or absence of risk factors.
When considering the effects of hor-
mone therapy on other important dis-
ease outcomes in a global model, there
was no net benefit in this study, even in
women considered to be at high risk of
fracture. Given the overall unfavorable
risk-benefit ratio and the availability of
other agents for prevention and treat-
ment of osteoporosis, treatment with
estrogenplusprogestinshouldnotberec-
ommended for prevention or for treat-
ment of osteoporosis in women with-
out vasomotor symptoms. Before the
combination of estrogen and progestin
is considered for the purpose of fracture
prevention, women should be fully
informed of the potential adverse effects.
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